Allworth Financial’s BioNTech BNTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$104K Sell
1,113
-44
-4% -$4.14K ﹤0.01% 1919
2026
Q1
$103K Buy
1,157
+35
+3% +$3.6K ﹤0.01% 1818
2025
Q4
$107K Sell
1,122
-139
-11% -$14K ﹤0.01% 1713
2025
Q3
$124K Buy
1,261
+48
+4% +$5.13K ﹤0.01% 1557
2025
Q2
$129K Buy
1,213
+1,118
+1,177% +$113K ﹤0.01% 1402
2025
Q1
$11.5K Sell
95
-6
-6% -$672 ﹤0.01% 2364
2024
Q4
$11.6K Buy
101
+23
+29% +$2.63K ﹤0.01% 2376
2024
Q3
$9.27K Sell
78
-3
-4% -$276 ﹤0.01% 2295
2024
Q2
$6.92K Buy
81
+27
+50% +$2.47K ﹤0.01% 2370
2024
Q1
$4.98K Sell
54
-137
-72% -$13.1K ﹤0.01% 2408
2023
Q4
$20.2K Buy
191
+8
+4% +$806 ﹤0.01% 1651
2023
Q3
$19.9K Hold
183
﹤0.01% 1519
2023
Q2
$19.8K Buy
183
+133
+266% +$15K ﹤0.01% 1549
2023
Q1
$6.23K Hold
50
﹤0.01% 1952
2022
Q4
$7.51K Hold
50
﹤0.01% 1777
2022
Q3
$7K Hold
50
﹤0.01% 1771
2022
Q2
$7K Hold
50
﹤0.01% 1659
2022
Q1
$9K Hold
50
﹤0.01% 1510
2021
Q4
$13K Hold
50
﹤0.01% 1282
2021
Q3
$14K Buy
+50
New +$15.9K ﹤0.01% 1144

Other funds holding BNTX

Allworth Financial's BNTX Position: Q2 2026 in Review

Allworth Financial reduced its BioNTech (BNTX) stake by 3.8% in Q2 2026, selling an estimated $4.14K and leaving 1,113 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #1919.

Allworth Financial first reported a position in BNTX in Q3 2021 and has held it in 20 quarters since. The position peaked at $129K in Q2 2025. 281 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

  • Allworth Financial held 1,113 shares of BioNTech worth $104K as of Q2 2026.
  • Allworth Financial sold 44 BioNTech shares in Q2 2026, an estimated $4.14K.
  • BioNTech made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #1919 holding.
  • Allworth Financial first reported a position in BioNTech in Q3 2021 and has held it in 20 quarters since.
  • Allworth Financial's BioNTech position peaked at $129K in Q2 2025.
  • 281 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.